Development of a biomimetic phospholipid vesicle-based permeation assay for the estimation of intestinal drug permeability

Journal of Pharmaceutical Sciences

Volumn 103, Issue 6, 2014, Pages 1882-1890

  Naderkhani, Elenaz ^a   Isaksson, Johan ^a   Ryzhakov, Alexey ^a,b   Flaten, Gøril Eide ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b INSTITUTE OF SOLUTION CHEMISTRY   (Russian Federation)

Author keywords

absorption; artificial membrane; cosolvent; in vitro model; intestinal absorption; lipid; liposome; screening; surfactants; tenside

Indexed keywords

ACETYLSALICYLIC ACID; ALPRENOLOL; ATENOLOL; CAFFEINE; CALCEIN; CHLORINE; CHLOROTHIAZIDE; CIMETIDINE; DICLOFENAC; ENALAPRIL; FLUFENAMIC ACID; FLURBIPROFEN; HYDROCHLOROTHIAZIDE; IBUPROFEN; METOPROLOL; METRONIDAZOLE; NADOLOL; NAPROXEN; PROPRANOLOL; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SULPIRIDE; TERBUTALINE; TIMOLOL; TRANEXAMIC ACID; DRUG; PHOSPHOLIPID;

ARTICLE; ASSAY; BIOMIMETICS; DRUG PENETRATION; INTESTINE ABSORPTION; LIPID COMPOSITION; LIPOPHILICITY; PERMEABILITY BARRIER; PH; PHOSPHOLIPID VESICLE; PHOSPHOLIPID VESICLE BASED PERMEATION ASSAY; PHYSICAL CHEMISTRY; ZETA POTENTIAL; INTESTINE; METABOLISM; PERMEABILITY;

BIOMIMETICS; INTESTINES; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS;

EID: 84901252441     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23954     Document Type: Article

References (37)

1. Artursson P,. 1990. Epithelial transport of drugs in cell-culture. 1. A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79 (6): 476-482.
2. Artursson P,. 1991. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carrier Syst 8 (4): 305-330.
3. Artursson P, Palm K, Luthman K,. 1996. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 22 (1-2): 67-84.
4. Araujo F, Sarmento B,. 2013. Towards the characterization of an in vitro triple co-culture intestine cell model for permeability studies. Int J Pharm 458 (1): 128-134.
5. Avdeef A,. 2003. High-throughput permeability and membrane retention measurement using artificial phospholipid membranes. Chimia 57 (1-2): 61-61.
6. Wohnsland F, Faller B,. 2001. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44 (6): 923-930.
7. Kansy M, Senner F, Gubernator K,. 1998. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41 (7): 1007-1010.
8. Sugano K, Hamada H, Machida M, Ushio H, Saitoh K, Terada K,. 2001. Optimized conditions of bio-mimetic artificial membrane permeation assay. Int J Pharm 228 (1-2): 181-188.
9. Kansy M, Avdeef A, Fischer H,. 2004. Advances in screening for membrane permeability: High-resolution PAMPA for medicinal chemists. Drug Discov Today Technol 1 (4): 349-355.
10. Avdeef A, Tsinman O,. 2006. PAMPA-A drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur J Pharm Sci 28 (1-2): 43-50.
11. Mandagere AK, Thompson TN, Hwang KK,. 2002. Graphical model for estimating oral bioavailability of drugs in humans and other species from their caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45 (2): 304-311.
12. Flaten GE, Dhanikula AB, Luthman K, Brandl M,. 2006. Drug permeability across a phospholipid vesicle based barrier: A novel approach for studying passive diffusion. Eur J Pharm Sci 27 (1): 80-90.
13. Yazdanian M, Glynn SL, Wright JL, Hawi A,. 1998. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15 (9): 1490-1494.
14. Flaten GE, Awoyemi O, Luthman K, Brandl M, Massing U,. 2009. The phospholipid vesicle-based permeability assay: 5. Development towards an automated procedure for high throughput permeability screening. JALA (14): 12-21.
15. Flaten GE, Bunjes H, Luthman K, Brandl M,. 2006. Drug permeability across a phospholipid vesicle-based barrier 2. Characterization of barrier structure, storage stability and stability towards pH changes. Eur J Pharm Sci 28 (4): 336-343.
16. Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J,. 2011. In vitro characterisation of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem 54: 2422-2432.
17. Hansen T, Ausbacher D, Flaten GE, Havelkova M, Strom MB,. 2011. Synthesis of cationic antimicrobial beta(2,2)-amino acid derivatives with potential for oral administration. J Med Chem 54 (3): 858-868.
18. Svenson J, Karstad R, Flaten GE, Brandsdal B-O, Brandl M, Svendsen JS,. 2009. Altered activity and physicochemical properties of short cationic antimicrobial peptides by incorporation of arginine analogues. Mol Pharm 6 (3): 996-1005.
19. Fischer SM, Flaten GE, Hagesæther E, Fricker G, Brandl M,. 2011. In vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay (PVPA): The influence of non-ionic surfactants. J Pharm Pharmacol 63 (8): 1022-1030.
20. Kanzer J, Tho I, Flaten GE, Magerlein M, Holig P, Fricker G, Brandl M,. 2010. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier. J Pharm Pharmacol 62 (11): 1591-1598.
21. Engesland A, Skar M, Hansen T, Skalko-Basnet N, Flaten GE,. 2013. New applications of phospholipid vesicle-based permeation assay: Permeation model mimicking skin barrier. J Pharm Sci 102 (5): 1588-1600.
22. Sugano K, Hamada H, Machida M, Ushio H,. 2001. High throughput prediction of oral absorption: Improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J Biomol Screen 6 (3): 189-196.
23. Ingebrigtsen L, Brandl M,. 2002. Determination of the size distribution of liposomes by SEC fractionation, and PCS analysis and enzymatic assay of lipid content. AAPS PharmSciTech 3 (2): 9-15.
24. Proulx P., 1991. Structure-function-relationships in intestinal brush-border membranes. Biochim Biophys Acta 1071 (3): 255-271.
25. Flaten GE, Luthman K, Vasskog T, Brandl M,. 2008. Drug permeability across a phospholipid vesicle-based barrier: 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability. Eur J Pharm Sci 34 (2-3): 173-180.
26. Avdeef A., 2003. Absorption and drug development; solubility, permeability and charge state. 1. New Jersey: Wiley-Interscience. pp 116-246.
27. Zhu C, Jiang L, Chen TM, Hwang KK,. 2002. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 37: 399-407.
28. Yee S,. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 14: 763-766.
29. Sugano K, Takata N, Machida M, Saitoh K, Terada K,. 2002. Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. Int J Pharm 241: 241-251.
30. Osterberg T, Svensson M, Lundahl P,. 2001. Chromatographic retention of drug molecules on immobilised liposomes prepared from egg phospholipids and from chemically pure phospholipids. Eur J Pharm Sci 12: 427-439.
31. Li X, Cooper MA,. 2012. Measurement of drug lipophilicity and pKa using acoustics. Anal Chem 84: 2609-2613.
32. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, Jarvenpaa KM,. 1990. Upper gastrointestinal (Gi) Ph in young, healthy-men and women. Pharm Res 7 (7): 756-761.
33. Malkia A, Murtomaki L, Urtti A, Kontturi K,. 2004. Drug permeation in biomembranes; In vitro and in silico prediction and influence of physicochemical properties. Eur J Pharm Sci 23 (1): 13-47.
34. Fischer SM, Buckley ST, Kirchmeyer W, Fricker G, Brandl M,. 2012. Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay. Int J Pharm 422 (1-2): 52-58.
35. Brandl M., 2001. Liposomes as drug carriers: A technological approach. Biotechnol Annu Rev 7: 59-85.
36. Dahan A, Miller JM,. 2012. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. AAPS J 14 (2): 244-251.
37. Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, Amidon GL, Dahan A,. 2011. The solubility-permeability interplay: Mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm 8 (5): 1848-1856.